Halozyme Therapeutics Inc
HALO
ISIN null / Valor 1814799
Halozyme Therapeutics Inc
UMushroom community rating:
About company
Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing novel drug delivery technologies. With over three decades of experience, the company has broadened its technological offerings to include a variety of auto-injectors for subcutaneous and intramuscular administration, catering to specific patient and therapeutic requirements. At the core of Halozyme's innovation is its ENHANZE® drug delivery technology, which leverages the proprietary enzyme rHuPH20 to enhance the subcutaneous delivery of injectable drugs and fluids. This technology has been commercially validated and is notable for its potential to significantly improve patient experience by transforming lengthy IV infusions into quick subcutaneous injections. Through its focus on creating custom-designed drug delivery devices and its ENHANZE® platform, Halozyme aims to address and reduce the treatment burden for patients across various therapeutic areas.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (18.11.2025):
Halozyme Therapeutics Inc's Q3 2025 financial results showcased record-breaking revenue figures and robust growth across multiple financial metrics. The quarter demonstrated strong year-over-year increases with royalty and overall revenue reaching new highs, improved profitability, and an upwardly revised financial outlook for the full year alongside important corporate developments such as a CFO transition and strategic acquisition activity.
Record Revenue Growth
During Q3 2025, Halozyme Therapeutics Inc reported a record royalty revenue of $236 million, up 52% year-over-year, which contributed to a total revenue of $354 million, marking a 22% increase compared to Q3 2024.
Enhanced Earnings and Profitability
The quarter saw net income rise by 28% to $175 million, with adjusted EBITDA up 35% to $248 million. GAAP diluted EPS increased 36% to $1.43, reflecting strong operational performance and enhanced profitability.
Upgraded 2025 Financial Guidance
Halozyme raised its 2025 guidance, now expecting total revenue between $1,300 million and $1,375 million, adjusted EBITDA of $885 million to $935 million, and non-GAAP diluted EPS between $6.10 and $6.50, reflecting enhanced growth expectations driven by increased royalty revenue and additional product contributions.
Strategic Initiatives and Corporate Updates
Key corporate highlights in Q3 2025 include the planned acquisition of Elektrofi for advancing subcutaneous drug delivery capabilities, a notable share repurchase program, significant new product indication approvals, and a CFO transition plan that sets the stage for continued strategic evolution at Halozyme Therapeutics Inc.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8298 M
Market cap (USD)
2,017,228
Daily traded volume (Shares)
48.63 / 47.65
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
